Isoprenalina Tillomed

Isoprenaline, the active ingredient in Isoprenalina Tillomed, is a beta‑adrenergic agonist presented as a sterile solution for intravenous or subcutaneous use. It is employed to increase heart rate and contractility in bradyarrhythmias and to provide bronchodilation in acute bronchospasm. The formulation complies with EU pharmaceutical standards and is intended for use under medical supervision.

GNH USA supplies Isoprenalina Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Isoprenaline acts on the beta‑adrenergic system to treat several acute cardiovascular and respiratory conditions. - Bradycardia: raises heart rate to maintain adequate cardiac output. - Heart block: improves conduction through the atrioventricular node. - Cardiac arrest: provides temporary circulatory support during resuscitation. - Bronchospasm: relaxes airway smooth muscle to relieve acute bronchoconstriction.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Tachycardia: rapid increase in heart rate. - Tremor: fine shaking of hands or limbs. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach discomfort.

Serious or Rare Side Effects: - Arrhythmias: potentially life‑threatening irregular heart rhythms. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: marked drop in blood pressure.

Careful assessment and monitoring are required before and during therapy. - Cardiac monitoring: continuous ECG and blood pressure observation. - Dose titration: start low and adjust based on clinical response. - Contraindications: avoid in patients with pheochromocytoma or uncontrolled hypertension. - Caution in ischemic heart disease: risk of worsening myocardial oxygen demand. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isoprenaline may interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: antagonize therapeutic effects and may precipitate severe bradycardia. - MAO inhibitors: can potentiate hypertensive responses. - Tricyclic antidepressants: increase risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance cardiac stimulation. - Digoxin: combined use can predispose to ventricular ectopy.